Status:
COMPLETED
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Lead Sponsor:
UNICEF
Collaborating Sponsors:
Pak Emirates Military Hospital
Conditions:
Covid19
Progression
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance. Condition or ...
Detailed Description
This study explores efficacy of HCQ (400mg BD on D0 and 200mg BD D1-D5) in reducing progression of Mild Covid-19 patients and decreasing viral load. Participants of study will be randomized 2:1 to re...
Eligibility Criteria
Inclusion
- Mild Corona virus disease (COVID-19)
- PCR confirmed infection
- Hospital admitted patients
Exclusion
- Moderate, severe and critical COVID-19
- day 0 CRP greater than 6mg/dl, ALC \< 1000 or evidence of infiltrates on X-ray chest
- comorbidity with life expectancy less than 6 months
- Contraindications to HCQ therapy
Key Trial Info
Start Date :
April 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2020
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT04491994
Start Date
April 10 2020
End Date
May 31 2020
Last Update
August 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan, 46000